Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Caina Technology Co., Ltd. (301122.SZ)
Jiangyin, CN
Caina Technology Co., Ltd. is dedicated to the research, development, manufacturing, and distribution of a variety of medical devices, particularly those related to injections and fluid delivery. The company's product portfolio includes essential sterile and single-use items such as safe, self-destructing syringes, disposable insulin syringes, and sterile insulin pen needles. They also provide sterile needles for blood collection and other specialized sterile medical instruments. Established in 2004, Caina Technology operates from its base in Jiangyin, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.44% | -1.47% | +15.16% | +4.90% | +10.83% | +28.86% | +63.25% | +4.12% | -39.76% | -39.76% | -39.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-8.5% Q1'26: +94.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-89.3% Q1'26: +83.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-11.6% Q1'26: -19.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-1.0% Q1'26: +8.3% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-0.3% Q1'26: +3.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.0% ★ Q1'26: -4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.60× ★ Q1'26: 4.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
442.05M
est: 679.00M (-34.9%)
|
465.49M
est: 410.54M (+13.4%)
|
410.47M
est: 410.54M (0.0%)
|
387.89M
est: 361.37M (+7.3%)
|
354.92M
est: 360.67M (-1.6%)
|
634.09M
634.09M – 634.09M
+75.8% YoY
|
761.76M
761.76M – 761.76M
+20.1% YoY
|
907.26M
907.26M – 907.26M
+19.1% YoY
|
| EBITDA |
172.93M
est: 252.22M (-31.4%)
|
210.81M
est: 152.50M (+38.2%)
|
161.51M
est: 152.50M (+5.9%)
|
95.61M
est: 117.96M (-18.9%)
|
52.55M
est: 117.73M (-55.4%)
|
206.98M
206.98M – 206.98M
+75.8% YoY
|
248.65M
248.65M – 248.65M
+20.1% YoY
|
296.15M
296.15M – 296.15M
+19.1% YoY
|
| EBIT |
152.07M
est: 208.43M (-27.0%)
|
183.70M
est: 126.02M (+45.8%)
|
130.30M
est: 126.02M (+3.4%)
|
57.63M
est: 86.33M (-33.2%)
|
-3.62M
est: 86.16M (-104.2%)
|
151.48M
151.48M – 151.48M
+75.8% YoY
|
181.98M
181.98M – 181.98M
+20.1% YoY
|
216.74M
216.74M – 216.74M
+19.1% YoY
|
| Net Income |
130.68M
est: 170.96M (-23.6%)
|
161.87M
est: 130.88M (+23.7%)
|
112.56M
est: 130.88M (-14.0%)
|
53.09M
est: 68.46M (-22.4%)
|
5.62M
est: 22.00M (-74.5%)
|
86.79M
86.79M – 86.79M
+294.4% YoY
|
108.80M
108.80M – 108.80M
+25.4% YoY
|
135.69M
135.69M – 135.69M
+24.7% YoY
|
| SGA |
23.75M
est: 17.76M (+33.7%)
|
32.04M
est: 10.74M (+198.3%)
|
34.61M
est: 10.74M (+222.2%)
|
46.74M
est: 33.26M (+40.5%)
|
47.15M
est: 33.20M (+42.0%)
|
58.37M
58.37M – 58.37M
+75.8% YoY
|
70.12M
70.12M – 70.12M
+20.1% YoY
|
83.51M
83.51M – 83.51M
+19.1% YoY
|
| EPS |
1.42
est: 1.38 (+2.6%)
|
1.76
est: 1.06 (+66.0%)
|
0.92
est: 1.06 (-13.2%)
|
0.43
est: 0.56 (-23.2%)
|
0.05
est: 0.18 (-74.4%)
|
0.71
0.71 – 0.71
+294.4% YoY
|
0.89
0.89 – 0.89
+25.4% YoY
|
1.11
1.11 – 1.11
+24.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Zhao | Deputy GM & Director | — | female |
| Jun Lu | Chairman & GM | — | male |
| Lijie Zhao | Deputy GM & Director | — | male |
| Lingyun Zha | Accounting Supervisor, Chief Financial Officer & Director | — | female |
| Weiwei Lu | Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 301122.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
